238 related articles for article (PubMed ID: 35836886)
21. CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis.
Li Q; Zhang L; Jiang J; Zhang Y; Wang X; Zhang Q; Wang Y; Liu C; Li F
BMC Med Genomics; 2019 Dec; 12(1):198. PubMed ID: 31870357
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.
Liu W; Xiang J; Wu X; Wei S; Huang H; Xiao Y; Zhai B; Wang T
Front Oncol; 2022; 12():899861. PubMed ID: 35669435
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
25. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
26. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
27. Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma.
Wen CY; Tsui KH; Chang CH; Chiu YH; Lin SA; Chu CY; Li CJ
J Oncol; 2022; 2022():9854788. PubMed ID: 35132321
[TBL] [Abstract][Full Text] [Related]
28. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
Zheng Y; Sun H; Yang S; Liu W; Jiang G
J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
[No Abstract] [Full Text] [Related]
29. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.
Lei X; Zhang M; Guan B; Chen Q; Dong Z; Wang C
Hum Genomics; 2021 Jun; 15(1):39. PubMed ID: 34187556
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel hub genes associated with lymph node metastasis of head and neck squamous cell carcinoma by completive bioinformatics analysis.
Lu H; Li L; Sun D; Duan Y; Yue K; Wu Y; Wang X
Ann Transl Med; 2021 Nov; 9(22):1678. PubMed ID: 34988187
[TBL] [Abstract][Full Text] [Related]
31. Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma.
Huang WT; Liu AG; Cai KT; He RQ; Li Z; Wei QJ; Chen MY; Huang JY; Yan WY; Zhou H; Chen G; Ma J
Am J Transl Res; 2019; 11(12):7538-7554. PubMed ID: 31934299
[TBL] [Abstract][Full Text] [Related]
32. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
Liu X; Liu X; Li J; Ren F
Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma.
Ye C; Wang H; Li Z; Xia C; Yuan S; Yan R; Yang X; Ma T; Wen X; Yang D
Transl Androl Urol; 2021 Jul; 10(7):3030-3045. PubMed ID: 34430406
[TBL] [Abstract][Full Text] [Related]
34. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer.
Liu Z; Pan R; Li W; Li Y
Front Oncol; 2021; 11():796795. PubMed ID: 35087757
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
37. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
38. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
39. Decoding signal transducer and activator of transcription 1 across various cancers through data mining and integrative analysis.
Munir H; Rana AT; Faheem M; Almutairi SM; Siddique T; Asghar S; Abdel-Maksoud MA; Mubarak A; Elkhamisy FAA; Studenik CR; Yaz H
Am J Transl Res; 2022; 14(6):3638-3657. PubMed ID: 35836889
[TBL] [Abstract][Full Text] [Related]
40. Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
Wang Y; Wang J; Tang Q; Ren G
PLoS One; 2021; 16(2):e0247827. PubMed ID: 33630978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
